India's Supreme Court says drug maker Novartis can't hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth of Novartis's price. Consumer advocates call it a major advance for access to generic drugs. The drug industry says it will chill companies' willingness to produce innovative products.
Support the news
More NPR or Explore Audio.